These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20355503)

  • 1. Numerical simulation of in-vitro dispersion and deposition of nanoparticles in dry-powder-inhaler aerosols.
    Mendes PJ; Pinto JF; Sousa JM
    J Nanosci Nanotechnol; 2010 Apr; 10(4):2791-7. PubMed ID: 20355503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential and constraints for the application of CFD combined with Lagrangian particle tracking to dry powder inhalers.
    Sommerfeld M; Cui Y; Schmalfuß S
    Eur J Pharm Sci; 2019 Feb; 128():299-324. PubMed ID: 30553814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dry powder inhaler with reduced mouth-throat deposition.
    Wang ZL; Grgic B; Finlay WH
    J Aerosol Med; 2006; 19(2):168-74. PubMed ID: 16796541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers.
    Li X; Vogt FG; Hayes D; Mansour HM
    J Pharm Sci; 2014 Sep; 103(9):2937-2949. PubMed ID: 24740732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling.
    Vulović A; Šušteršič T; Cvijić S; Ibrić S; Filipović N
    Eur J Pharm Sci; 2018 Feb; 113():171-184. PubMed ID: 29054499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dry powder aerosol delivery systems: current and future research directions.
    Chan HK
    J Aerosol Med; 2006; 19(1):21-7. PubMed ID: 16551211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental measurements of particle deposition in three proximal lung bifurcation models with an idealized mouth-throat.
    Zhang Y; Finlay WH
    J Aerosol Med; 2005; 18(4):460-73. PubMed ID: 16379621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.
    Kolanjiyil AV; Kleinstreuer C; Sadikot RT
    Comput Biol Med; 2017 May; 84():247-253. PubMed ID: 27836120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro monodisperse aerosol deposition in a mouth and throat with six different inhalation devices.
    DeHaan WH; Finlay WH
    J Aerosol Med; 2001; 14(3):361-7. PubMed ID: 11693848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deposition and fine particle production during dynamic flow in a dry powder inhaler: a CFD approach.
    Milenkovic J; Alexopoulos AH; Kiparissides C
    Int J Pharm; 2014 Jan; 461(1-2):129-36. PubMed ID: 24296048
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery.
    Li X; Vogt FG; Hayes D; Mansour HM
    Eur J Pharm Sci; 2014 Feb; 52():191-205. PubMed ID: 24215736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting the deposition of inhaled porous drug particles.
    Musante CJ; Schroeter JD; Rosati JA; Crowder TM; Hickey AJ; Martonen TB
    J Pharm Sci; 2002 Jul; 91(7):1590-600. PubMed ID: 12115821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar and Turbuhaler inhalers.
    Zhang Y; Gilbertson K; Finlay WH
    J Aerosol Med; 2007; 20(3):227-35. PubMed ID: 17894531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of oral airway geometry characteristics on the diffusional deposition of inhaled nanoparticles.
    Xi J; Longest PW
    J Biomech Eng; 2008 Feb; 130(1):011008. PubMed ID: 18298184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers.
    Glover W; Chan HK; Eberl S; Daviskas E; Verschuer J
    Int J Pharm; 2008 Feb; 349(1-2):314-22. PubMed ID: 17904774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deposition of inhaled particles in the mouth and throat of asthmatic subjects.
    Svartengren K; Lindestad PA; Svartengren M; Bylin G; Philipson K; Camner P
    Eur Respir J; 1994 Aug; 7(8):1467-73. PubMed ID: 7957832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Respimat Soft Mist Inhaler using a concurrent CFD and in vitro approach.
    Worth Longest P; Hindle M
    J Aerosol Med Pulm Drug Deliv; 2009 Jun; 22(2):99-112. PubMed ID: 18956950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of mouthpiece geometry on the aerosol delivery performance of a dry powder inhaler.
    Coates MS; Chan HK; Fletcher DF; Chiou H
    Pharm Res; 2007 Aug; 24(8):1450-6. PubMed ID: 17404813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A simple mechanistic model of deposition of water-soluble aerosol particles in the mouth and throat.
    Mitsakou C; Mitrakos D; Neofytou P; Housiadas C
    J Aerosol Med; 2007; 20(4):519-29. PubMed ID: 18158723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validating CFD Predictions of Pharmaceutical Aerosol Deposition with In Vivo Data.
    Tian G; Hindle M; Lee S; Longest PW
    Pharm Res; 2015 Oct; 32(10):3170-87. PubMed ID: 25944585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.